艾伯维Abbvie Inc (ABBV) 2016年年度报告「NYSE」.pdf

1、2016 annual report on form 10-k2017 notice of annual meeting&proxy statementAbbVie 1 North Waukegan Road,North Chicago,IL 60064 U.S.ACopyright 2017 AbbVie.All rights reserved.7188_AbbvieCover.indd 12/7/17 7:49 PMabout abbvieAbbVi e i s a global,res earch-bas edbi opharmaceuti cal company formedi n 2

2、013 followi ng s eparati on fromAbbott Laboratori es.The company smi s s i on i s to us e i ts experti s e,dedi catedpeople and uni que approach to i nnovati onto develop and market advanced therapi esthat addres s s ome of the world s mos tcomplex and s eri ous di s eas es.Togetherwi th i ts wholly

3、-owned s ubs i di ary,Pharmacycli cs,AbbVi e employs approxi mately 29,000 people worldwi de and marketsmedi ci nes i n more than 170 countri es.For further i nformati on on the companyand i ts people,portfoli o and commi tments,pleas e vi s i t www.abbvi e.c om.13NOV2012213657664DEC201212233206Dear

4、 AbbVie Stockholder,When AbbVie launched in 2013,we began our journey with a commitment.A commitment toall stakeholders to build an innovation-driven biopharmaceutical company capable of achievingsustainable top-tier performance with a consistent stream of innovative new medicines.Throughour first f

5、our years,weve made great strides on that mission and are well positioned to continueour record of performance and progress.By nearly any measure,our results over our first four years place us solidly in the top tier ofour peer group.Since inception,weve delivered compounded annual revenue and adjus

6、tedearnings per share(EPS)growth of 11 percent and 15 percent,respectively.Over the same period,our dividend has grown 60 percent,contributing to a total shareholder return of 111 percent,thehighest among our peer group.In addition,weve launched more than a dozen new products orexpanded indications